Unlike the weekly Wegovy shot, the tablet is only recommended for adults and has to be taken daily. But the pills “offer an oral alternative to weekly subcutaneous injections that may be more convenient for some patients,” the EMA said.
Studies have shown that Wegovy pills can help patients lose on average 13.6 percent of their body weight.
The U.S. Food and Drug Administration approved the oral version of Wegovy in December 2025, and its competitor, Eli Lilly’s pill Foundayo, in April.
The European Commission must now rubber-stamp the EMA’s decision for the Wegovy pill to be officially approved — usually within a few months.
